Convalescent Plasma Therapy against COVID-19: An Update on the
Changing Facets of the ongoing Pandemic

Saquib   Shahabe   Abullais; Suraj      Arora; Shadma      Wahab; Vishakha      Grover; Mohammed   Yahya   Alshahrani; Shaik   Mohamed   Shamsudeen; Shaik      Mohammed  Asif; Amel   Ibrahim   Faragalla; Mohamed   Fadul   Elagib
Abstract

The severe respiratory infections in the current pandemic coronavirus disease-19 (COVID-19) have influenced more or less every human life. The first person to get infected with this virus was reported in the capital of Hubei province (Wuhan), China, in late December 2019. Since the disease has been declared a pandemic, research scholars and experts have been manufacturing new vaccines or targeted therapies to curb the spread of SARS-CoV-2. However, only limited options have emerged so far, which yet require complete scientific validation by long-term data collection regarding safety and efficacy. In the wake of the recent emerging wave of the pandemic viz omicron variant, changing facets of the viral genome and dearth of preventative and therapeutic possibilities for the management of COVID-19, the usage of Convalescent Plasma Therapy (CPT) may be looked at as a potentially viable option of treatment in the existing situation. Earlier, immune plasma has been used with success in the management of H1N1 influenza virus, MERS-CoV, and SARS-CoV-1 epidemics. In the present unpredictable situation created by the COVID-19 pandemic, the CPT is used with a positive outcome amongst many infected individuals in different parts of the world with acceptable efficacy. This article aimed to present an up-to-date evaluation of existing literature on the efficacy of convalescent plasma as a potential therapy, its safety and effectiveness and the challenges in treating COVID-19.
Graphical Abstract

[1]
COVID-19 Map - Johns hopkins coronavirus resource center.  Available from: https://coronavirus.jhu.edu/map.html [Accessed on January 16, 2022].

[2]
COVID-19 coronavirus pandemic.  Available from: worldometers.info/coronavirus/ [accessed on March 6, 2022]

[3]
International Monetary Fund (IMF). World Economic Outlook, October 2021: After-Effects of the COVID-19 Pandemic: Prospects for Medium-Term Economic Damage. International Monetary Fund: Washington, DC, 2021. Available from: https://www.imf.org/en/Publications/WEO/Issues/2021/10/12/world-economic-outlook-october-2021

[4]
Tackling the mental health impact of the COVID-19 crisis: An integrated, whole-of-society response. OECD, 2021. Available from: https://www.oecd.org/coronavirus/policy-responses/tackling-the-mental-health-impact-of-the-covid-19-crisis-an-integrated-whole-of-society-response-0ccafa0b/

[5]
Saudi MoH protocol for patients suspected of confirmed with COVID-19. Supportive care and antiviral treatment of suspected or confirmed COVID-19 infection. 2022. Available from: https://www.moh.gov.sa/Ministry/MediaCenter/Publications/Documents/MOH-therapeutic-protocol-for-COVID-19.pdf

[6]
Infectious diseases society of america guidelines on the treatment and management of patients with COVID-19. 2022. Available from: www.idsociety.org/COVID19

[7]
Libster, R.; Pérez Marc, G.; Wappner, D.; Coviello, S.; Bianchi, A.; Braem, V.; Esteban, I.; Caballero, M.T.; Wood, C.; Berrueta, M.; Rondan, A.; Lescano, G.; Cruz, P.; Ritou, Y.; Fernández Viña, V.; Álvarez Paggi, D.; Esperante, S.; Ferreti, A.; Ofman, G.; Ciganda, Á.; Rodriguez, R.; Lantos, J.; Valentini, R.; Itcovici, N.; Hintze, A.; Oyarvide, M.L.; Etchegaray, C.; Neira, A.; Name, I.; Alfonso, J.; López Castelo, R.; Caruso, G.; Rapelius, S.; Alvez, F.; Etchenique, F.; Dimase, F.; Alvarez, D.; Aranda, S.S.; Sánchez Yanotti, C.; De Luca, J.; Jares Baglivo, S.; Laudanno, S.; Nowogrodzki, F.; Larrea, R.; Silveyra, M.; Leberzstein, G.; Debonis, A.; Molinos, J.; González, M.; Perez, E.; Kreplak, N.; Pastor Argüello, S.; Gibbons, L.; Althabe, F.; Bergel, E.; Polack, F.P. Early high-titer plasma therapy to prevent severe COVID-19 in older adults. N. Engl. J. Med.,  2021, 384(7), 610-618.
 [http://dx.doi.org/10.1056/NEJMoa2033700] [PMID:  33406353]

[8]
Rejeki, M.S.; Sarnadi, N.; Wihastuti, R.; Fazharyasti, V.; Samin, W.Y.; Yudhaputri, F.A.; Johar, E.; Nurainy, N.; Bachtiar, N.S.; Muljono, D.H. Convalescent plasma therapy in patients with moderate-to-severe COVID-19: A study from Indonesia for clinical research in low- and middle-income countries. E. Clin. Med.,  2021, 36, 100931.
 [http://dx.doi.org/10.1016/j.eclinm.2021.100931] [PMID:  34104878]

[9]
Ripoll, J.G.; van Helmond, N.; Senefeld, J.W.; Wiggins, C.C.; Klassen, S.A.; Baker, S.E.; Larson, K.F.; Murphy, B.M.; Andersen, K.J.; Ford, S.K.; Casadevall, A.; Joyner, M.J. Convalescent plasma for infectious diseases: Historical framework and use in COVID-19. Clin. Microbiol. Newsl.,  2021, 43(4), 23-32.
 [http://dx.doi.org/10.1016/j.clinmicnews.2021.02.001] [PMID:  33564204]

[10]
Mair-Jenkins, J.; Saavedra-Campos, M.; Baillie, J.K.; Cleary, P.; Khaw, F.M.; Lim, W.S.; Makki, S.; Rooney, K.D.; Nguyen-Van-Tam, J.S.; Beck, C.R. The effectiveness of convalescent plasma and hyperimmune immunoglobulin for the treatment of severe acute respiratory infections of viral etiology: A systematic review and exploratory meta-analysis. J. Infect. Dis.,  2015, 211(1), 80-90.
 [http://dx.doi.org/10.1093/infdis/jiu396] [PMID:  25030060]

[11]
Agarwal, A.; Mukherjee, A.; Kumar, G.; Chatterjee, P.; Bhatnagar, T.; Malhotra, P. PLACID trial collaborators convalescent plasma in the management of moderate COVID-19 in adults in india: Open label phase ii multicenter randomised controlled trial (PLACID Trial). BMJ,  2020, 371, m3939.
 [http://dx.doi.org/10.1136/bmj.m3939] [PMID:  33093056]

[12]
Simonovich, V.A.; Burgos Pratx, L.D.; Scibona, P.; Beruto, M.V.; Vallone, M.G.; Vázquez, C.; Savoy, N.; Giunta, D.H.; Pérez, L.G.; Sánchez, M.L.; Gamarnik, A.V.; Ojeda, D.S.; Santoro, D.M.; Camino, P.J.; Antelo, S.; Rainero, K.; Vidiella, G.P.; Miyazaki, E.A.; Cornistein, W.; Trabadelo, O.A.; Ross, F.M.; Spotti, M.; Funtowicz, G.; Scordo, W.E.; Losso, M.H.; Ferniot, I.; Pardo, P.E.; Rodriguez, E.; Rucci, P.; Pasquali, J.; Fuentes, N.A.; Esperatti, M.; Speroni, G.A.; Nannini, E.C.; Matteaccio, A.; Michelangelo, H.G.; Follmann, D.; Lane, H.C.; Belloso, W.H. PlasmAr study group. A randomized trial of convalescent plasma in COVID-19 severe pneumonia. N. Engl. J. Med.,  2021, 384(7), 619-629.
 [http://dx.doi.org/10.1056/NEJMoa2031304] [PMID:  33232588]

[13]
Franchini, M.; Liumbruno, GM.; Piacentini, G.; Glingani, C.; Zaffanello, M. The three pillars of COVID-19 convalescent plasma therapy. Life,  2021, 11(4), 354.
 [http://dx.doi.org/10.3390/life11040354]

[14]
Coronavirus (COVID-19) vaccinations 2022.  Available from: https://ourworldindata.org/covid-vaccinations [Accessed on March 11, 2022

[15]
Arora, S.; Grover, V.; Saluja, P.; Algarni, Y.A.; Saquib, S.A.; Asif, S.M.; Batra, K.; Alshahrani, M.Y.; Das, G.; Jain, R.; Ohri, A. Literature review of omicron: A grim reality amidst covid-19. Microorganisms,  2022, 10(2), 451.
 [http://dx.doi.org/10.3390/microorganisms10020451] [PMID:  35208905]

[16]
Liu, L.; Iketani, S.; Guo, Y.; Chan, J.F-W.; Wang, M.; Liu, L.; Luo, Y.; Chu, H.; Huang, Y.; Nair, M.S. Striking antibody evasion manifested by the omicron variant of SARS-CoV-2. Nature,  2021, 602(7898), 676-681.
 [http://dx.doi.org/10.1038/s41586-021-04388-0] [PMID:  35016198]

[17]
Mohiuddin, M.; Kasahara, K. Investigating the aggressiveness of the COVID-19 Omicron variant and suggestions for possible treatment options. Respir. Med.,  2022, 191, 106716.
 [http://dx.doi.org/10.1016/j.rmed.2021.106716] [PMID:  34923286]

[18]
Sahin, G.; Akbal-Dagistan, O.; Culha, M.; Erturk, A.; Basarir, N.S.; Sancar, S.; Yildiz-Pekoz, A. Antivirals and the potential benefits of orally inhaled drug administration in COVID-19 treatment. J. Pharm. Sci.,  2022, 111(10), 2652-2661.
 [http://dx.doi.org/10.1016/j.xphs.2022.06.004] [PMID:  35691607]

[19]
Wahab, S.; Ahmad, I.; Usmani, S.; Ahmad, M.P. Efficacy of dexamethasone for the treatment of COVID-19 infection: A perspective review. Curr. Drug Deliv.,  2021, 18(5), 546-554.
 [http://dx.doi.org/10.2174/18755704MTEwhNDgg4] [PMID:  33023445]

[20]
Mohamed, Y.; El-Maradny, Y.A.; Saleh, A.K.; Nayl, A.A.; El-Gendi, H.; El-Fakharany, E.M. A comprehensive insight into current control of COVID-19: Immunogenicity, vaccination, and treatment. Biomed. Pharmacother.,  2022, 153, 113499.
 [http://dx.doi.org/10.1016/j.biopha.2022.113499] [PMID:  36076589]

[21]
Wu, H.; Ji, C.; Dai, R.; Hei, P.; Liang, J.; Wu, X.; Li, Q.; Yang, J.; Mao, W.; Guo, Q. Traditional chinese medicine treatment for COVID-19: An overview of systematic reviews and meta-analyses. J. Integr. Med.,  2022, 20(5), 416-426.
 [http://dx.doi.org/10.1016/j.joim.2022.06.006]

[22]
Wahab, S.; Ahmad, I.; Irfan, S.; Baig, M.H.; Farouk, A-E.; Dong, J-J. Use of natural compounds as a potential therapeutic agent against COVID-19. Curr. Pharm. Des.,  2021, 27(9), 1144-1152.
 [http://dx.doi.org/10.2174/18734286MTEykOTUaz] [PMID:  33388014]

[23]
Franchini, M.; Glingani, C.; Liumbruno, G.M. Potential mechanisms of action of convalescent plasma in COVID-19. Diagnosis,  2021, 8(4), 413-420.
 [http://dx.doi.org/10.1515/dx-2020-0161] [PMID:  33652503]

[24]
Focosi, D.; Franchini, M. COVID-19 convalescent plasma therapy: Hit fast, hit hard! Vox Sang.,  2021, 116(9), 935-942.
 [http://dx.doi.org/10.1111/vox.13091] [PMID:  33794556]

[25]
Mayo clinic convalescent plasma therapy 2022. Available from:https://www.mayoclinic.org/tests-procedures/convalescent-plasma-therapy/about/pac-[accessed on Feb 24, 2022

[26]
Casadevall, A.; Pirofski, L. The convalescent sera option for containing COVID-19. J. Clin. Invest.,  2020, 130(4), 1545-1548.
 [http://dx.doi.org/10.1172/JCI138003] [PMID:  32167489]

[27]
Cecil, R.L. Effects of very early serum treatment in pneumococcus type I pneumonia. J. Am. Med. Assoc.,  1937, 108(9), 689-692.
 [http://dx.doi.org/10.1001/jama.1937.02780090001001]

[28]
Flexner, S. The results of the serum treatment in thirteen hundred cases of epidemic meningitis. J. Exp. Med.,  1913, 17(5), 553-576.
 [http://dx.doi.org/10.1084/jem.17.5.553] [PMID:  19867668]

[29]
Tiberghien, P.; Lamballerie, X.; Morel, P.; Gallian, P.; Lacombe, K.; Yazdanpanah, Y. Collecting and evaluating convalescent plasma for COVID-19 treatment: Why and how? Vox Sang.,  2020, 115(6), 488-494.
 [http://dx.doi.org/10.1111/vox.12926] [PMID:  32240545]

[30]
Epstein, J.; Burnouf, T. Points to consider in the preparation and transfusion of COVID-19 convalescent plasma. Vox Sang.,  2020, 115(6), 485-487.
 [http://dx.doi.org/10.1111/vox.12939] [PMID:  32319102]

[31]
Advancing transfusion and cellular therapies worldwide aabb), COVID-19 convalescent plasma collection: Donor eligibility, processing, labeling, and distribution. 2020. Available from: https://abhh.org.br/wp-content/uploads/2020/04/AABB_COVID-19-Convalescent- Plasma-Collection.pdf

[32]
Kaufmann, S.H.E. Remembering emil von behring: from tetanus treatment to antibody cooperation with phagocytes. MBio,  2017, 8(1), e00117-e17.
 [http://dx.doi.org/10.1128/mBio.00117-17] [PMID:  28246359]

[33]
Wong, H.K.; Lee, C.K. Pivotal role of convalescent plasma in managing emerging infectious diseases. Vox Sang.,  2020, 115(7), 545-547.
 [http://dx.doi.org/10.1111/vox.12927] [PMID:  32240549]

[34]
Luke, T.C.; Casadevall, A.; Watowich, S.J.; Hoffman, S.L.; Beigel, J.H.; Burgess, T.H. Hark back: Passive immunotherapy for influenza and other serious infections. Crit. Care Med.,  2010, 38(4), e66-e73.
 [http://dx.doi.org/10.1097/CCM.0b013e3181d44c1e] [PMID:  20154602]

[35]
Bloch, E.M.; Shoham, S.; Casadevall, A.; Sachais, B.S.; Shaz, B.; Winters, J.L.; van Buskirk, C.; Grossman, B.J.; Joyner, M.; Henderson, J.P.; Pekosz, A.; Lau, B.; Wesolowski, A.; Katz, L.; Shan, H.; Auwaerter, P.G.; Thomas, D.; Sullivan, D.J.; Paneth, N.; Gehrie, E.; Spitalnik, S.; Hod, E.A.; Pollack, L.; Nicholson, W.T.; Pirofski, L.; Bailey, J.A.; Tobian, A.A.R. Deployment of convalescent plasma for the prevention and treatment of COVID-19. J. Clin. Invest.,  2020, 130(6), 2757-2765.
 [http://dx.doi.org/10.1172/JCI138745] [PMID:  32254064]

[36]
Hung, I.F.N.; To, K.K.W.; Lee, C.K.; Lee, K.L.; Chan, K.; Yan, W.W.; Liu, R.; Watt, C.L.; Chan, W.M.; Lai, K.Y.; Koo, C.K.; Buckley, T.; Chow, F.L.; Wong, K.K.; Chan, H.S.; Ching, C.K.; Tang, B.S.F.; Lau, C.C.Y.; Li, I.W.S.; Liu, S.H.; Chan, K.H.; Lin, C.K.; Yuen, K.Y. Convalescent plasma treatment reduced mortality in patients with severe pandemic influenza A (H1N1) 2009 virus infection. Clin. Infect. Dis.,  2011, 52(4), 447-456.
 [http://dx.doi.org/10.1093/cid/ciq106] [PMID:  21248066]

[37]
Yeh, K.M.; Chiueh, T.S.; Siu, L.K.; Lin, J.C.; Chan, P.K.S.; Peng, M.Y.; Wan, H.L.; Chen, J.H.; Hu, B.S.; Perng, C.L.; Lu, J.J.; Chang, F.Y. Experience of using convalescent plasma for severe acute respiratory syndrome among healthcare workers in a Taiwan hospital. J. Antimicrob. Chemother.,  2005, 56(5), 919-922.
 [http://dx.doi.org/10.1093/jac/dki346] [PMID:  16183666]

[38]
Cheng, Y.; Wong, R.; Soo, Y.O.Y.; Wong, W.S.; Lee, C.K.; Ng, M.H.L.; Chan, P.; Wong, K.C.; Leung, C.B.; Cheng, G. Use of convalescent plasma therapy in SARS patients in Hong Kong. Eur. J. Clin. Microbiol. Infect. Dis.,  2005, 24(1), 44-46.
 [http://dx.doi.org/10.1007/s10096-004-1271-9] [PMID:  15616839]

[39]
Soo, Y.O.Y.; Cheng, Y.; Wong, R.; Hui, D.S.; Lee, C.K.; Tsang, K.K.S.; Ng, M.H.L.; Chan, P.; Cheng, G.; Sung, J.J.Y. Retrospective comparison of convalescent plasma with continuing high-dose methylprednisolone treatment in SARS patients. Clin. Microbiol. Infect.,  2004, 10(7), 676-678.
 [http://dx.doi.org/10.1111/j.1469-0691.2004.00956.x] [PMID:  15214887]

[40]
Chun, S.; Chung, C.R.; Ha, Y.E.; Han, T.H.; Ki, C.S.; Kang, E.S.; Park, J.K.; Peck, K.R.; Cho, D. Possible transfusion-related acute lung injury following convalescent plasma transfusion in a patient with middle east respiratory syndrome. Ann. Lab. Med.,  2016, 36(4), 393-395.
 [http://dx.doi.org/10.3343/alm.2016.36.4.393] [PMID:  27139619]

[41]
Ko, J.H.; Seok, H.; Cho, S.Y.; Ha, Y.E.; Baek, J.Y.; Kim, S.H.; Kim, Y.J.; Park, J.K.; Chung, C.R.; Kang, E.S.; Cho, D.; Müller, M.A.; Drosten, C.; Kang, C.I.; Chung, D.R.; Song, J.H.; Peck, K.R. Challenges of convalescent plasma infusion therapy in Middle East respiratory coronavirus infection: A single centre experience. Antivir. Ther.,  2018, 23(7), 617-622.
 [http://dx.doi.org/10.3851/IMP3243] [PMID:  29923831]

[42]
Yunus, K.T.M.; Badruddin, I.A.; Saquib, S.A.; Mohamed, R.; Arora, S.; Mohammed, M.A.K.; Shamsuddin, S.V.; Khateeb, S.; Khan, A.A.; Grover, V. Convalescent plasma therapy: A treatment of choice for COVID-19 during current pandemic. Indian J. Pharm. Sci.,  2022, 84(1), 235-245.
 [http://dx.doi.org/10.36468/pharmaceutical-sciences.spl.438]

[43]
Kumar, S.; Sharma, V.; Priya, K. Battle against COVID-19: Efficacy of convalescent plasma as an emergency therapy. Am. J. Emerg. Med.,  2021, 41, 244-246.
 [http://dx.doi.org/10.1016/j.ajem.2020.05.101] [PMID:  32505474]

[44]
Rajendran, K.; Krishnasamy, N.; Rangarajan, J.; Rathinam, J.; Natarajan, M.; Ramachandran, A. Convalescent plasma transfusion for the treatment of COVID-19: Systematic review. J. Med. Virol.,  2020, 92(9), 1475-1483.
 [http://dx.doi.org/10.1002/jmv.25961] [PMID:  32356910]

[45]
Bakhtawar, N.; Usman, M.; Khan, MMU. Convalescent plasma therapy and its effects on COVID-19 patient outcomes: A systematic review of current literature. Cureus,  2020, 12(8)e9535
 [http://dx.doi.org/10.7759/cureus.9535]

[46]
Li, L.; Zhang, W.; Hu, Y.; Tong, X.; Zheng, S.; Yang, J.; Kong, Y.; Ren, L.; Wei, Q.; Mei, H.; Hu, C.; Tao, C.; Yang, R.; Wang, J.; Yu, Y.; Guo, Y.; Wu, X.; Xu, Z.; Zeng, L.; Xiong, N.; Chen, L.; Wang, J.; Man, N.; Liu, Y.; Xu, H.; Deng, E.; Zhang, X.; Li, C.; Wang, C.; Su, S.; Zhang, L.; Wang, J.; Wu, Y.; Liu, Z. Effect of convalescent plasma therapy on time to clinical improvement in patients with severe and life-threatening COVID-19. JAMA,  2020, 324(5), 460-470.
 [http://dx.doi.org/10.1001/jama.2020.10044] [PMID:  32492084]

[47]
Sharma, A.; Seth, T.; Elavarasi, A.; Sahoo, R.K. Shalimar; Madan, K.; Nischal, N.; Soneja, M.; Garg, P.; Prasad, K. Convalescent plasma therapy for COVID-19: A systematic review. Natl. Med. J. India,  2020, 33(4), 213-221.
 [http://dx.doi.org/10.4103/0970-258X.296202] [PMID:  34045376]

[48]
Vegivinti, C.T.R.; Pederson, J.M.; Saravu, K.; Gupta, N.; Evanson, K.W.; Kamrowski, S.; Schmidt, M.; Barrett, A.; Trent, H.; Dibas, M.; Reierson, N.L.; Mikoff, N.; Pisipati, S.; Joseph, B.A.; Selvan, P.T.; Dmytriw, A.A.; Pulakurthi, Y.S.; Keesari, P.R.; Sriram, V.; Chittajallu, S.; Brinjikji, W.; Katamreddy, R.R.; Chibbar, R.; Davis, A.R.; Malpe, M.; Mishra, H.K.; Kallmes, K.M.; Hassan, A.E. Efficacy of convalescent plasma therapy for COVID-19: A systematic review and meta-analysis. J. Clin. Apher.,  2021, 36(3), 470-482.
 [http://dx.doi.org/10.1002/jca.21881] [PMID:  33544910]

[49]
Ayub, A.; Agarwal, N.; Mishra, S. Convalescent plasma therapy in COVID-19 and discharge status: A systematic review. J. Family Med. Prim. Care,  2021, 10(10), 3876-3881.
 [http://dx.doi.org/10.4103/jfmpc.jfmpc_2429_20] [PMID:  34934695]

[50]
Casadevall, A.; Tobian, A.A.R. Convalescent plasma for COVID-19 - encouraging signals of efficacy. Br. J. Haematol.,  2021, 192(4), 681-682.
 [http://dx.doi.org/10.1111/bjh.17270] [PMID:  33524158]

[51]
Casarola, G.; D’Abbondanza, M.; Curcio, R.; Alcidi, R.; Campanella, T.; Rossi, R.; Fusaro, J.; Gandolfo, V.; Di Giuli, C.; Laoreti, C.; Veca, V.; Leone, M.C.; Pucci, G.; Vaudo, G. Efficacy of convalescent plasma therapy in immunocompromised patients with COVID-19: A case report. Clin. Infect. Pract.,  2021, 12, 100096.
 [http://dx.doi.org/10.1016/j.clinpr.2021.100096] [PMID:  34490417]

[52]
Hacibekiroğlu, T.; Kalpakçı, Y. Genç, AC Efficacy of convalescent plasma according to blood groups in COVID-19 patients. Turk. J. Med. Sci.,  2021, 51(1), 45-48.
 [http://dx.doi.org/10.3906/sag-2007-59]

[53]
Marano, G.; Vaglio, S.; Pupella, S.; Facco, G.; Catalano, L.; Liumbruno, G.M.; Grazzini, G. Convalescent plasma: New evidence for an old therapeutic tool? Blood Transfus.,  2016, 14(2), 152-157.
 [PMID:  26674811]

[54]
Xinhua, T.S.C.I.O. Fighting COVID-19: China in action; The State Council Information Office of the People’s Republic of China, 2020. 

[55]
Peiris, J.S.M.; Chu, C.M.; Cheng, V.C.C.; Chan, K.S.; Hung, I.F.N.; Poon, L.L.M.; Law, K.I.; Tang, B.S.F.; Hon, T.Y.W.; Chan, C.S.; Chan, K.H.; Ng, J.S.C.; Zheng, B.J.; Ng, W.L.; Lai, R.W.M.; Guan, Y.; Yuen, K.Y. Clinical progression and viral load in a community outbreak of coronavirus-associated SARS pneumonia: A prospective study. Lancet,  2003, 361(9371), 1767-1772.
 [http://dx.doi.org/10.1016/S0140-6736(03)13412-5] [PMID:  12781535]

[56]
Li, G.; Chen, X.; Xu, A. Profile of specific antibodies to the SARS-associated coronavirus. N. Engl. J. Med.,  2003, 349(5), 508-509.
 [http://dx.doi.org/10.1056/NEJM200307313490520] [PMID:  12890855]

[57]
Luke, T.C.; Kilbane, E.M.; Jackson, J.L.; Hoffman, S.L. Meta-analysis: convalescent blood products for Spanish influenza pneumonia: A future H5N1 treatment? Ann. Intern. Med.,  2006, 145(8), 599-609.
 [http://dx.doi.org/10.7326/0003-4819-145-8-200610170-00139] [PMID:  16940336]

[58]
MacLennan, S.; Barbara, J.A.J. Risks and side effects of therapy with plasma and plasma fractions. Best Pract. Res. Clin. Haematol.,  2006, 19(1), 169-189.
 [http://dx.doi.org/10.1016/j.beha.2005.01.033] [PMID:  16377549]

[59]
Zhou, X.Z.; Zhao, M.; Wang, F.S.; Jiang, T.J.; Li, Y.G.; Nie, W.M.; Zhou, Z.P.; Wang, Y.; He, J.; Fan, R.; Zhao, J.M.; Zhang, X.W. Epidemiologic features, clinical diagnosis and therapy of first cluster of patients with severe acute respiratory syndrome in Beijing area. Zhonghua Yi Xue Za Zhi,  2003, 83(12), 1018-1022.
 [PMID:  12899773]

[60]
Hendrickson, J.E.; Hillyer, C.D. Noninfectious serious hazards of transfusion. Anesth. Analg.,  2009, 108(3), 759-769.
 [http://dx.doi.org/10.1213/ane.0b013e3181930a6e] [PMID:  19224780]

[61]
Use of convalescent whole blood or plasma collected from patients recovered from Ebola virus disease for transfusion, as an empirical treatment during. World Health Organization, 2014; pp. 1-19.

[62]
Anudeep, T.C.; Jeyaraman, M.; Shetty, D.U.; Raj, H.; Ss, A.; Somasundaram, R.; Kumar, V.; Jain, R.; Dilip, S. Convalescent plasma as a plausible therapeutic option for nCOVID-19: A review. J. Clin. Trials,  2020, 10, 1-7.
 [http://dx.doi.org/10.35248/2167-0870.20.10.409]

[63]
Sullivan, H.C.; Roback, J.D. Convalescent plasma: Therapeutic hope or hopeless strategy in the SARS-CoV-2 pandemic. Transfus. Med. Rev.,  2020, 34(3), 145-150.
 [http://dx.doi.org/10.1016/j.tmrv.2020.04.001] [PMID:  32359788]

[64]
Uhr, J.W.; Baumann, J.B. Antibody formation I. The suppression of antibody formation by passively administered antibody. J. Exp. Med.,  1961, 113(5), 935-957.
 [http://dx.doi.org/10.1084/jem.113.5.935] [PMID:  13779027]

[65]
Duan, K.; Liu, B.; Li, C.; Zhang, H.; Yu, T.; Qu, J.; Zhou, M.; Chen, L.; Meng, S.; Hu, Y.; Peng, C.; Yuan, M.; Huang, J.; Wang, Z.; Yu, J.; Gao, X.; Wang, D.; Yu, X.; Li, L.; Zhang, J.; Wu, X.; Li, B.; Xu, Y.; Chen, W.; Peng, Y.; Hu, Y.; Lin, L.; Liu, X.; Huang, S.; Zhou, Z.; Zhang, L.; Wang, Y.; Zhang, Z.; Deng, K.; Xia, Z.; Gong, Q.; Zhang, W.; Zheng, X.; Liu, Y.; Yang, H.; Zhou, D.; Yu, D.; Hou, J.; Shi, Z.; Chen, S.; Chen, Z.; Zhang, X.; Yang, X. Effectiveness of convalescent plasma therapy in severe COVID-19 patients. Proc. Natl. Acad. Sci.,  2020, 117(17), 9490-9496.
 [http://dx.doi.org/10.1073/pnas.2004168117] [PMID:  32253318]

[66]
Wu, F.; Wang, A.; Liu, M.; Wang, Q.; Chen, J.; Xia, S.; Ling, Y.; Zhang, Y.; Xun, J.; Lu, L. Neutralizing antibody responses to sars-cov-2 in a COVID-19 recovered patient cohort and their implications. SSRN,  2020, 2020.03.30.20047365.
 [http://dx.doi.org/10.2139/ssrn.3566211]

[67]
Shen, C.; Wang, Z.; Zhao, F.; Yang, Y.; Li, J.; Yuan, J.; Wang, F.; Li, D.; Yang, M.; Xing, L. Treatment of 5 critically ill patients with COVID-19 with convalescent plasma. JAMA2020,  323, 1582-1589.
 [http://dx.doi.org/10.1001/jama.2020.4783]

[68]
Zhang, B.; Liu, S.; Tan, T.; Huang, W.; Dong, Y.; Chen, L.; Chen, Q.; Zhang, L.; Zhong, Q.; Zhang, X.; Zou, Y.; Zhang, S. Treatment with convalescent plasma for critically ill patients with severe acute respiratory syndrome coronavirus 2 infection. Chest,  2020, 158(1), e9-e13.
 [http://dx.doi.org/10.1016/j.chest.2020.03.039] [PMID:  32243945]

[69]
Ye, M.; Fu, D.; Ren, Y.; Wang, F.; Wang, D.; Zhang, F.; Xia, X.; Lv, T. Treatment with convalescent plasma for COVID-19 patients in Wuhan, China. J. Med. Virol.,  2020, 92(10), 1890-1901.
 [http://dx.doi.org/10.1002/jmv.25882] [PMID:  32293713]

[70]
Ahn, J.Y.; Sohn, Y.; Lee, S.H.; Cho, Y.; Hyun, J.H.; Baek, Y.J.; Jeong, S.J.; Kim, J.H.; Ku, N.S.; Yeom, J.S.; Roh, J.; Ahn, M.Y.; Chin, B.S.; Kim, Y.S.; Lee, H.; Yong, D.; Kim, H.O.; Kim, S.; Choi, J.Y. Use of convalescent plasma therapy in two COVID-19 patients with acute respiratory distress syndrome in Korea. J. Korean Med. Sci.,  2020, 35(14)e149
 [http://dx.doi.org/10.3346/jkms.2020.35.e149] [PMID:  32281317]

[71]
Roback, J.D.; Guarner, J. Convalescent plasma to treat COVID-19. JAMA,  2020, 323(16), 1561-1562.
 [http://dx.doi.org/10.1001/jama.2020.4940] [PMID:  32219429]

[72]
Denise, M. Emergency use authorization for COVID-19 convalescent plasma. U.S. Food & Drug Admin., U.S. Dep’t of Health & Human Servs. 2020. Available from: https://www.fda.gov/media/141477/download

[73]
Sullivan, D.J.; Gebo, K.A.; Shoham, S. Randomized controlled trial of early outpatient COVID-19 treatment with high-titer convalescent plasma. medRxiv,  , 2021.12.10.21267485.
 [http://dx.doi.org/10.1101/2021.12.10.21267485]

[74]
Focosi, D.; Massimo, F.; Michael, J.J.; Arturo, C. Comparative analysis of antibody responses from COVID-19 convalescents receiving various vaccines reveals consistent high neutralizing activity for SARS-CoV-2 variant of concern. OMICRO. Nmed. Rxiv,  2021, 12(24), 21268317.
 [http://dx.doi.org/10.1101/2021.12.24.21268317]
Cite As
Current Pharmaceutical Biotechnology

Convalescent Plasma Therapy against COVID-19: An Update on the Changing Facets of the ongoing Pandemic

Abstract

Graphical Abstract
